Andressa da Matta Durans currently holds an INOVA FIOCRUZ postdoctoral fellowship from the Center for Technological Development in Health (CDTS) at the Oswaldo Cruz Foundation (FIOCRUZ). She earned a doctorate in tropical medicine (2018) at FIOCRUZ under the mentorship of Dr. Angela Junqueira and Dr. William Provance Jr. in recognition of her research into high-performance immunological reagents for diagnosing chronic Trypanosoma cruzi infections, which are responsible for Chagas disease. She has experience in molecular biology, biotechnology, recombinant proteins, Sanger sequencing, and serological diagnosis. During her doctoral research, she contributed to the development of a proteinaceous receptacle as an innovative solution to using linear B cells in generating immunological reagents. Developed with Dr. Provance, Dr. Salvatore Giovanni De Simone, and Dr. Paloma Napoleão Pêgo at the CDTS, this tool has been patented in Brazil, the United States of America, China, and India, with worldwide rights reserved for the bioengineering of chimeric recombinant proteins for use in diagnostic testing and vaccine development. This bioengineering made viable the construction of chimeric proteins for SARS-CoV-2, Mayaro fever, and chronic Chagas disease.
Andressa da Matta Durans currently holds an INOVA FIOCRUZ postdoctoral fellowship from the Center for Technological Development in Health (CDTS) at the Oswaldo Cruz Foundation (FIOCRUZ). She earned a doctorate in tropical medicine (2018) at FIOCRUZ under the mentorship of Dr. Angela Junqueira and Dr. William Provance Jr. in recognition of her research into high-performance immunological reagents for diagnosing chronic Trypanosoma cruzi infections, which are responsible for Chagas disease. She has experience in molecular biology, biotechnology, recombinant proteins, Sanger sequencing, and serological diagnosis. During her doctoral research, she contributed to the development of a proteinaceous receptacle as an innovative solution to using linear B cells in generating immunological reagents. Developed with Dr. Provance, Dr. Salvatore Giovanni De Simone, and Dr. Paloma Napoleão Pêgo at the CDTS, this tool has been patented in Brazil, the United States of America, China, and India, with worldwide rights reserved for the bioengineering of chimeric recombinant proteins for use in diagnostic testing and vaccine development. This bioengineering made viable the construction of chimeric proteins for SARS-CoV-2, Mayaro fever, and chronic Chagas disease.